Ashley Bond
University of Liverpool
32 Papers
23 Citations
Ashley Bond is an academic researcher from University of Liverpool. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 6, co-authored 18 publications. Previous affiliations of Ashley Bond include Royal Liverpool and Broadgreen University Hospital NHS Trust.
Chat about Author
Papers
Review article: cytomegalovirus and inflammatory bowel disease
TL;DR: The outcome for patients with CMV reactivation appears worse than that for patients without reactivation, but it is not entirely clear whether CMV is a contributor or a bystander and if treatment with anti‐virals alters the course of inflammatory bowel disease (IBD).
139
Artificial intelligence & clinical nutrition: What the future might have in store.
Ashley Bond,Kevin Mccay,Simon Lal +2 more
TL;DR: Artificial Intelligence has the potential to transform clinical nutrition, but its integration into clinical practice should be carefully monitored to ensure patient safety and benefit.
24
New technologies and techniques to improve adenoma detection in colonoscopy
Ashley Bond,Sanchoy Sarkar +1 more
TL;DR: New technologies and techniques that improve Adenoma detection rate are reviewed, both in terms of the endoscopes themselves and adjuncts to current systems, and the key role that continued medical education plays in improving the quality of colonoscopy and thus ADR is highlighted.
20
New-Generation High-Definition Colonoscopes Increase Adenoma Detection when Screening a Moderate-Risk Population for Colorectal Cancer.
Ashley Bond,P O’Toole,Gareth Fisher,Sreedhar Subramanian,Neil Haslam,Chris Probert,Trevor Cox,Sanchoy Sarkar +7 more
TL;DR: This retrospect observational study of 395 patients undergoing colonoscopy as part of the UK Bowel Cancer Screening Programme demonstrated that the Olympus H290 LUCERA ELITE high‐definition colonoscopes improved adenoma detection within the moderate‐risk population.
20
Concurrent immunomodulator therapy is associated with higher adalimumab trough levels during scheduled maintenance therapy
TL;DR: Adalimumab trough levels were significantly higher in patients on concurrent immunomodulators during maintenance therapy, and there was a trend towards a lower adalimumAB trough level in patients with elevated calprotectin.
12